Associate
Emily Gabranski focuses her practice on patent litigation, primarily in the biotechnology and pharmaceutical areas. She assists with Hatch-Waxman litigation related to Abbreviated New Drug Applications (ANDA) and post-grant proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO).
Prior to joining Finnegan, Emily conducted research in cellular and molecular neurobiology. Her research focused on transmitter modulation of neuronal network interactions. She coauthored two peer-reviewed publications in scientific journals and presented her research at the Society for Neuroscience annual meeting.
While in law school, Emily worked as a summer associate at Finnegan, where she assisted in litigation matters before the PTAB and federal district courts. She also worked in the Vanderbilt Intellectual Property Clinic, assisting clients with USPTO filings and state trademark registration.
Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.
Represented Novartis against Genzyme related to recombinant adeno-associated virus vector technology used in Novartis’ blockbuster, breakthrough gene therapy Zolgensma®. The case settled after four patents were invalidated during claim construction, five patents found not literally infringed, and institution of multiple inter partes reviews (IPRs).
1:21-cv-01736, 1:23-cv-00554, D. Del., Judge Andrews
American Regent, Inc. v. Pharmacosmos Therapeutics Inc. et al.
Counsel for American Regent in litigation in the District of New Jersey against Pharmacosmos and their branded drug, Monoferric®, related to American Regent patents covering the use of iron carbohydrate complexes for the treatment of iron deficiency diseases. The case resulted in a favorable settlement for our client.
3:20-cv-01350, D.N.J., Judges Goodman, Martinotti, Quraishi
PGR2020-00009, PTAB, Judges Tornquist, Franklin, Wisz
Eli Lilly and Company v. Teva Pharmaceuticals International
Member of a team that represented Eli Lilly in multiple inter partes review (IPR) proceedings involving antibody therapies.
IPR2018-01422; -01423; -01424; -01425; -01426; -01427; -01710, -01711, -01712, PTAB
Duchesnay, Inc. v. Actavis Laboratories Inc. and Mylan Pharmaceuticals, Inc.
1:14-cv-00912, D. Del., Judges Robinson, Fallon
Vifor (International) AG and American Regent, Inc. v. Mylan Labs. Ltd. et al.
3:19-cv-13955, 3:19-cv-16305, D.N.J., Judges Wolfson, Arpert
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company
Represented Eli Lilly in patent litigations involving antibody therapies.
1:18-cv-12029, D. Mass., Judge Burroughs
Event
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Articles
D. Mass. Patent Litigation Update: February 2024 D. Mass. Patent Litigation Update: February 2024
April 1, 2024
Event
Patent Inventorship: Best Practices for Determination and Correction Patent Inventorship: Best Practices for Determination and Correction
May 5, 2022
Articles
Patents and Debating Their Place in the US Constitution Patents and Debating Their Place in the US Constitution
June 2020
CIPA JournalPress Release
32 Finnegan Attorneys Recognized by Best Lawyers 32 Finnegan Attorneys Recognized by Best Lawyers
August 17, 2023
Best LawyersAward/Ranking
54 Finnegan Attorneys Named to 2022 Capital Pro Bono Honor Roll 54 Finnegan Attorneys Named to 2022 Capital Pro Bono Honor Roll
July 21, 2023
Press Release
62 Finnegan Attorneys Named to 2019 Capital Pro Bono Honor Roll 62 Finnegan Attorneys Named to 2019 Capital Pro Bono Honor Roll
June 8, 2020
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.